Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting

Cell therapy, also known as cell transplantation therapy, refers to the infusion of normal or bioengineered human cells into cancer patients to inhibit tumor growth. Cell therapy is not broken down by the body's metabolism, and has fewer side effects than traditional chemotherapy and radiotherapy. It has shown great development potential in the field of cancer treatment. In cellular immunotherapy, glucose metabolism plays an important role in cellular immunotherapy. The generation of highly purified and metabolically adapted chimeric antigen receptor immune cells is a huge challenge for cellular immunotherapy. The precise regulation of metabolic pathways will enhance the effect of immunotherapy. Chimeric antigen receptor T-cell therapy is the only FDA-approved chimeric antigen receptor-based therapy. CD BioGlyco provides solutions for the screening and identification of biomarkers related to glucose metabolism in the development of chimeric antigen receptor T cell therapy, optimization of chimeric antigen receptor T cells, and management of cytokine release syndrome.

Model of metabolic manipulation of T cells Fig. 1 Model of metabolic manipulation of T cells (Marchesi F, et al., 2020)

What We Do

  • Identification and screening of glucose metabolism-related biomarkers

Chimeric antigen receptor T-cell therapy provides a remarkable distinguishing signal between cancer cells and normal cells and is the most effective target for immune recognition and destruction. Through the MOPCGM platform, we can analyze multiple omics data to find biomarkers for different cancer types that can be used for chimeric antigen receptor T cell therapy.

  • Optimization of chimeric antigen receptor T cells based on glucose metabolism

A large number of studies have found that in the process of cancer progression, abnormal glucose metabolism has an important impact on the immune function of T cells. Chimeric antigen receptor T cells require specific metabolic conditions to maintain proliferation and specific potency. Therefore, we optimize the chimeric antigen receptor T cells by targeting the glucose metabolism pathway and expanding the effective therapeutic range of chimeric antigen receptor T cell therapy in cancer treatment.

The specific services we can provide are as follows, including but not limited to:

  • Optimization of chimeric antigen receptor T cell structure
  • Resolving the dilemma faced by chimeric antigen receptor expansion in vitro and in vivo through regulation of glucose metabolism pathways
  • Overcoming the cytokine release syndrome of chimeric antigen receptor T cell therapy by modulation of glucose metabolism
  • One-stop cytokine release syndrome management service

Cytokine release syndrome, also known as cytokine storm, is a severe systemic inflammatory response caused by the activation of immune cells and the release of a large number of cytokines. It is also the most common adverse reaction of chimeric antigen receptor T cell therapy. The laboratory detected increased serum levels of cytokines such as interleukin-6 and tumor necrosis factor in patients with cytokine release syndrome. These cytokines also have a role in regulating glucose metabolism, and cytokine release syndrome may also be caused by cytokines. Regulation of tumor cell glucose metabolism affects the effect of chimeric antigen receptor T cell therapy. CD BioGlyco can provide in vitro and in vivo cytokine release syndrome detection services.

The specific services we can provide are as follows, including but not limited to:

  • Cytokine release assay based on MOPCGM platform
  • Toxicity assessment of cytokine release syndrome

Applications

  • Early recognition and diagnosis of cytokine release syndrome.
  • Specific treatment development for cytokine release syndrome.
  • Analysis of the effect of chimeric antigen receptor T cell therapy on tumor glucose metabolism.

CD BioGlyco provides solutions to problems related to glucose metabolism during the development of a one-stop chimeric antigen receptor T cell therapy. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.

Reference:

  1. Marchesi F, et al. Manipulation of Glucose Availability to Boost Cancer Immunotherapies. Cancers (Basel). 2020 Oct 12; 12(10): 2940.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.